Advertisement

Topics

Arquer Diagnostics awarded funding under Innovate UK’s Biocatalyst programme

05:30 EST 1 Mar 2017 | Zyme Communications

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer
Sunderland, UK, 1st March 2017: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for bladder cancer, today announced that it has been awarded £70,000 funding under Innovate UK’s Biocatalyst programme, to be awarded over a 12 month period, starting 1st March 2017. The funding will be used to support preparations for an international clinical study to evaluate Arquer’s MCM5 ELISA-based non-invasive test for prostate cancer, as the Company expands the application of its technology into a wider range of cancers.

Arquer’s diagnostic test, the MCM5-ELISA, detects the presence of minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells, to accurately diagnose cancer. MCM proteins are excellent biomarkers, being directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. The funding follows the recent appointment of Nadia Whittley as CEO.

The study will utilise urine and semen samples from up to 100 patients, in order to inform the design of a wider clinical trial expected to commence in late 2017.

Commenting on the funding, Stuart McCracken, PhD, Consultant Urologist Sunderland Royal Hospital, UK, and UK Clinical Investigator for the study said: “There is an urgent need to find, and robustly validate, a novel cancer biomarker of prostate cancer. Studies such as this provide evidence that may support a change in the diagnostic pathway and start to allow reductions in expensive and unnecessary prostate biopsies which are very unpopular with patients and are a major financial burden to healthcare providers.”

Nadia Whittley, CEO, Arquer Diagnostics, commented: “We are delighted that Innovate UK has identified the potential opportunity provided by our diagnostic test, particularly as we move forward to commercialise our MCM5 ELISA. The MCM5 ELISA is expected to significantly reduce the number of patients undergoing invasive and costly diagnostic procedures such as cystoscopy and biopsy,  as it offers highly accurate diagnostic results from small amounts of body fluid.”

For more information, please visit www.arquerdx.com/

About Arquer Diagnostics Ltd

Arquer Diagnostics (Arquer) is a private, UK-based diagnostics company focused on the development and commercialisation of non-invasive immunoassay diagnostic tests for cancer. Arquer’s diagnostic test, the MCM5 ELISA, detects the presence of minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells, in urine. MCM proteins are excellent biomarkers, being directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. Arquer’s test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK. The non-invasive, ELISA tests being developed by Arquer meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The MCM5 ELISA is expected to significantly reduce the number of patients undergoing invasive and costly techniques such as cystoscopy and biopsy, as they offer highly accurate diagnostic results from small amounts of body fluid.

About Innovate UK

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.

For further information visit www.innovateuk.gov.uk

For further information please contact: Lorna Cuddon, Zyme Communications Tel: +44 (0)7811 996 942 Email: lorna.cuddon@zymecommunications.com NEXT ARTICLE

More From BioPortfolio on "Arquer Diagnostics awarded funding under Innovate UK’s Biocatalyst programme"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...